QuidelOrtho (QDEL) Stock Overview
Provides diagnostic testing solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
QDEL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
QuidelOrtho Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.54 |
| 52 Week High | US$49.45 |
| 52 Week Low | US$22.05 |
| Beta | 0.15 |
| 1 Month Change | -4.96% |
| 3 Month Change | -8.09% |
| 1 Year Change | -39.94% |
| 3 Year Change | -63.14% |
| 5 Year Change | -88.23% |
| Change since IPO | 56.09% |
Recent News & Updates
Recent updates
QuidelOrtho Corporation (NASDAQ:QDEL) Surges 32% Yet Its Low P/S Is No Reason For Excitement
May 14
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
May 12QuidelOrtho (NASDAQ:QDEL) Has No Shortage Of Debt
Apr 25QuidelOrtho Corporation's (NASDAQ:QDEL) Business And Shares Still Trailing The Industry
Mar 30
Leadership Changes And Cost Reductions Will Shape Future Profitability
Leadership changes and strategic initiatives aim for innovation and efficiency, enhancing revenue and net margins.QuidelOrtho: Growth Struggles And Negative GAAP Earnings Continue To Disinterest Investors
Feb 20QuidelOrtho: Highly Levered With Questionable Growth
Nov 26Lacklustre Performance Is Driving QuidelOrtho Corporation's (NASDAQ:QDEL) Low P/S
Nov 17QuidelOrtho (NASDAQ:QDEL) Seems To Be Using A Lot Of Debt
Sep 15QuidelOrtho Corporation (NASDAQ:QDEL) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Aug 09QuidelOrtho: Attractive Valuation Despite Weak Performance
Apr 13We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt
Apr 08QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues
Feb 15Shareholder Returns
| QDEL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -10.8% | -2.1% | -0.8% |
| 1Y | -39.9% | -3.1% | 16.2% |
Return vs Industry: QDEL underperformed the US Medical Equipment industry which returned -1.7% over the past year.
Return vs Market: QDEL underperformed the US Market which returned 17.4% over the past year.
Price Volatility
| QDEL volatility | |
|---|---|
| QDEL Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QDEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: QDEL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 6,600 | Brian Blaser | www.quidelortho.com |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
QuidelOrtho Corporation Fundamentals Summary
| QDEL fundamental statistics | |
|---|---|
| Market cap | US$1.81b |
| Earnings (TTM) | -US$466.40m |
| Revenue (TTM) | US$2.74b |
Is QDEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QDEL income statement (TTM) | |
|---|---|
| Revenue | US$2.74b |
| Cost of Revenue | US$1.45b |
| Gross Profit | US$1.30b |
| Other Expenses | US$1.76b |
| Earnings | -US$466.40m |
Last Reported Earnings
Jun 29, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.87 |
| Gross Margin | 47.29% |
| Net Profit Margin | -17.01% |
| Debt/Equity Ratio | 93.5% |
How did QDEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/25 17:30 |
| End of Day Share Price | 2025/09/25 00:00 |
| Earnings | 2025/06/29 |
| Annual Earnings | 2024/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
QuidelOrtho Corporation is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Mark Massaro | Canaccord Genuity |
| Patrick Donnelly | Citigroup Inc |